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a  b  s  t  r  a  c  t
Background:  The increased  possibility  of  bioterrorism  has  led  to  reinitiation  of  smallpox  vaccination.
In  Korea,  more  than  30 years  have  passed  since  the  last smallpox  vaccinations,  and  even people  who
were  previously  vaccinated  are  not  regarded  as  adequately  protected  against  smallpox.  We  evaluated
the  efﬁcacy  and  safety  of CJ-50300,  a newly  developed  cell  culture-derived  smallpox  vaccine,  in healthy
adults  previously  vaccinated  against  smallpox.
Methods: We  conducted  an  open  label,  single  arm,  phase  III clinical  trial to  evaluate  the  efﬁcacy  and  safety
of  CJ-50300.  Healthy  volunteers,  previously  vaccinated  against  smallpox,  born  between  1950  and  1978
were  enrolled.  CJ-50300  was  administered  with  a bifurcated  needle  over  the  deltoid  muscle  according  to
the  recommended  method.  The  rate  of  the  cutaneous  take  reaction,  humoral  immunogenicity,  and  safety
of  the  vaccine  was assessed.
Results: Of  145  individuals  enrolled  for  vaccination,  139  completed  the  study.  The overall  rates  of
cutaneous  take  reactions  and  humoral  immunogenicity  were  95.0%  (132/139)  and  88.5%  (123/139),
respectively.  Although  95.9%  (139/145)  reported  adverse  events  related  to vaccination,  no  serious  adverse
reactions  were  observed.
Conclusion: CJ-50300  can  be  used  safely  and  effectively  in  healthy  adults  previously  vaccinated  against
smallpox.
©  201 .. Introduction
Smallpox in nature was eradicated from the world by an orga-
ized vaccination program, and in South Korea routine vaccination
gainst smallpox has been discontinued since 1978 [1]. However,
he increased possibility of bioterrorism has led to reinitiation of
mallpox vaccination during the last decade [2]. The traditional
rst-generation smallpox vaccines produced until 1982 were com-
osed of live attenuated vaccinia virus grown in the skin of calves
3,4], a method no longer acceptable under current standards [5,6].
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A few cell culture-derived smallpox vaccines have been developed
and evaluated for efﬁcacy and safety to replace the ﬁrst generation
smallpox vaccines [4,6–8], but only one of these second generation
smallpox vaccines, ACAM2000, has been approved by the United
States Food and Drug Administration [9].
More than 30 years have passed since the last smallpox vacci-
nations in Korea, and even people who  were previously vaccinated
are not regarded as adequately protected against smallpox. There-
fore, we conducted an open label, single arm, phase III clinical trial
to evaluate the efﬁcacy and safety of CJ-50300 in healthy subjects
previously vaccinated against smallpox.
2. Methods
Open access under CC BY-NC-ND license2.1. Vaccine preparation
CJ-50300  was derived from vaccinia virus strain ATCC VR-118
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train), adapted to replicate in MRC-5 cells under serum-free con-
itions. Harvested cells were lysed, centrifugated and ﬁltrated. The
nal bulk was aseptically ﬁlled in glass vials and freeze-dried.
reclinical studies in mice and cynomolgus monkeys have shown
hat CJ-50300 is similar in cutaneous reactogenicity, immuno-
enicity, protection, and neurovirulence to the ﬁrst-generation
accine Lancy-Vaxina (BernaBiotech, Bern, Switzerland), and tests
f MRC-5 cells and the ﬁnal vaccine product have revealed no
vidence of adventitious agents [10]. In previously conducted
linical trials, CJ-50300 vaccinees exhibited cutaneous take reac-
ions, acquired adequate humoral and cellular immunity, and none
f 141 vaccinees (123 and 18, respectively) experienced serious
dverse reactions [8,11]. The titer of vaccinia virus in CJ-50300 was
.0 × 108 plaque-forming units (pfu)/mL [10].
.2. Ethics statement
The  study was approved by the Institutional Review Board
f Seoul National University Hospital and the Korea Food
nd Drug Administration (ClinicalTrials.gov registration number:
CT01317238). All volunteers attended a brieﬁng, received an
nformation brochure, and provided written informed consent in
ccordance with the principles of the Declaration of Helsinki before
creening.
.3. Study design and participants
An  open label, single arm, phase III clinical trial to evalu-
te the efﬁcacy and safety of CJ-50300 in previously vaccinated
ealthy subjects was conducted at the Clinical Research Insti-
ute of Seoul National University Hospital from November 2010
hrough November 2011. Healthy volunteers who  were previ-
usly vaccinated against smallpox, and were born between 1950
nd 1978 (thus, 32–60 years olds) were enrolled (November 2nd,
010–May 17th, 2011). Prior smallpox vaccination was  veriﬁed by
onﬁrming the typical scar. Exclusion criteria included the con-
raindications for smallpox vaccination noted in the guidelines
ublished by the United States Centers for Disease Control and
revention [12]. Medical histories, physical examinations, and lab-
ratory tests were used to conﬁrm that the participants were
ealthy and satisﬁed all inclusion criteria but none of the exclu-
ion criteria. Screening laboratory tests included measurements of
lucose in serum, blood urea nitrogen, creatinine, sodium, potas-
ium, chloride, calcium, phosphorus, uric acid, total bilirubin, total
rotein, albumin, aspartate transaminase, alanine transaminase,
lkaline phosphatase, -glutamyl transferase, total cholesterol, lac-
ate dehydrogenase, creatine kinase, creatine kinase-MB, hepatitis
 virus surface antigen, antibody to hepatitis C virus, antibody to
uman immunodeﬁciency virus, urinalysis, urine human chorionic
onadotrophin for women, prothrombin time, activated partial
hromboplastin time, complete blood cell count with differential
ount, chest radiograph and electrocardiogram (ECG).
.4.  Vaccine administration, follow-up procedures, and safety
valuation
Freeze-dried CJ-50300 was reconstituted with 0.3mL
lycerin–phenol diluent and used within 1 h. Two  experienced
accinators administered the reconstituted vaccine to all subjects,
ccording to the recommended method [12], using a bifurcated
eedle (BD, Franklin Lakes, NJ) to create 15 percutaneous punc-
ures over the deltoid muscle. All of the vaccinees were examined
n post-vaccination days (PVDs) 3, 7, 14, 21, and 28. The vacci-
ation site was photographed, and a semi-permeable dressing of
egaderm (3M Corporate, St. Paul, MN)  and gauze were applied to
he site until a scab formed.1 (2013) 5239– 5242
At each visit the vaccinees returned a completed daily diary con-
taining a questionnaire about adverse events, and received a new
diary. Symptoms were assessed as mild (present, but not bother-
some), moderate (bothersome, but not precluding the performance
of routine activities), or severe (precluding the performance of nor-
mal  activities). At each visit a new medical history was  taken,
and a physical examination and laboratory tests, including crea-
tine kinase, creatine kinase-MB, and lactate dehydrogenase levels,
were performed. ECGs and blood samples were obtained before
and 28 days after vaccination. Additional ECGs were obtained for
vaccinees reporting chest pain or dyspnea. Serious adverse reac-
tions were deﬁned as encephalitis, acute myopericarditis, eczema
vaccinatum, progressive vaccinia, and death [2].
2.5. Outcome measures
The  primary endpoint was  the rate of cutaneous take reaction,
which was deﬁned as a vesicular or pustular lesion or an area of
deﬁnite palpable induration or congestion surrounding a central
lesion (a crust or ulcer) occurring at the vaccination site at any
of PVDs 6–8 [12]. Humoral immunogenicity was  the secondary
endpoint. Humoral immunogenicity was evaluated by a validated
plaque-reduction neutralization (PRN) test, as described previously
[8]. The 50%PRN titer (PRNT50) was deﬁned as the serum dilution
yielding a 50% reduction in vaccinia virus concentration (pfu/mL).
Humoral immunogenicity was deﬁned as positive if the PRNT50 had
increased by a factor of 4 or more on PVD 28.
2.6. Statistical analysis
We  calculated a sample size sufﬁcient for a lower 95% conﬁ-
dence limit of the cutaneous take reaction rate of at least 86% (the
mean take reaction rate for ACAM2000 in a Phase II and Phase III
trial in previously vaccinated subjects), assuming a true rate of 93%,
derived from the results of previous studies [13], by the binominal
test. Allowing for a 10% loss to follow-up, a sample size of at least
145 was  required for a statistical power of 80%.
Categorical variables were compared using Fisher’s exact test or
Pearson’s 2 test, as appropriate. Continuous variables were com-
pared using Student’s t test or analysis of variance (ANOVA), as
appropriate. All tests of signiﬁcance were two-tailed, and differ-
ences were deemed statistically signiﬁcant at P ≤ 0.05. Statistical
analyses were performed using SAS (version 9.1).
3.  Results
3.1. Baseline clinical characteristics
Of  185 subjects screened for eligibility, 145 were enrolled for
vaccination and 40 were excluded: 29 did not meet the inclusion
criteria, and 11 refused to participate. One individual withdrew
from the study before completion and 144 completed the study.
Five participants were found to be ineligible after enrollment, and
139 were eventually included in the efﬁcacy analysis. All 145 par-
ticipants who  received at least 1 dose of the vaccine were included
in the safety analysis (Fig. 1). The mean (±SD) age of the participants
was 44.8 (±7.9) years, and 40 (27.6%) were male.
3.2. Cutaneous take reaction
A  take reaction was  observed in 95.0% (132/139) of the vac-
cinees. The diameters (mean ± SD) of the vesicles and palpable
indurations were largest on PVD 14 (5.3 ± 3.2 mm and 9.0 ± 4.1 mm,
respectively), and the diameter of the erythemas was  largest on
PVD 7 (18.8 ± 9.1 mm)  (Table 1).
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Table  1
Cutaneous take reactions of 139 vaccinees who received CJ-50300, a cell culture-
derived  second-generation smallpox vaccine.
Characteristics Size of skin lesion, mean ± SD (mm)
Diameter of vesicle
PVD  7 3.4 ± 2.0
PVD 14 5.3 ± 3.2
PVD 21 4.9 ± 3.1
Diameter of induration
PVD  7 7.6 ± 3.0
PVD 14 9.0 ± 4.1



















Common adverse events of 145 vaccinees who received CJ-50300, a cell culture-
derived  second-generation smallpox vaccine.
Characteristics Severity of adverse events
Milda Moderateb Severec
Systemic adverse events (%) 107 (73.8) 19 (13.1) 0 (0.0)
Fever  5 (3.5) 0 (0.0) 0 (0.0)
Chill  38 (26.2) 7  (4.8) 0 (0.0)
Myalgia  48 (33.1) 7 (4.8) 0 (0.0)
Fatigue  66 (45.5) 7 (4.8) 0 (0.0)
Headache  62 (42.8) 9 (6.2) 0 (0.0)
Chest  pain 9 (6.2) 0 (0.0) 0 (0.0)
Dyspnea  3 (2.1) 0 (0.0) 0 (0.0)
Local  adverse reactions (%) 136 (93.8) 25  (17.2) 0 (0.0)
Pruritus  at vaccination site 132 (91.0) 15  (10.3) 0 (0.0)
Pain  at vaccination site 97 (66.9) 14 (9.7) 0 (0.0)
Axillary  pain or lymphadenopathy 63 (43.5) 10 (6.9) 0 (0.0)
a Mild symptoms were present but not bothersome.
bPVD  7 18.8 ± 9.1
PVD 14 16.5 ± 7.1
PVD 21 12.9 ± 5.7
.3. Humoral immunogenicity
The  PRN response rate on PVD 28 was 88.5% (123/139). The geo-
etric mean (±SD) of the PRNT50 was 9.8 (±2.78) before and 223.6
±3.11) after vaccination.
.4.  Adverse events
Of  the 145 vaccinees, 139 (95.9%) reported adverse events: 137
94.5%) reported at least 1 symptom or sign at the vaccination site,
nd 108 (74.5%) reported systemic symptoms. The self-reporting
iaries revealed that 9 vaccinees (6.2%) experienced chest pain, and
 (2.1%) dyspnea (Table 2). The severity of chest pain and dysp-
ea was mild and transient in all cases. Physical examination and
aboratory tests including ECG and cardiac enzymes revealed no
bnormal ﬁndings in any subject. There were no serious adverse
eactions related to vaccination, and no inadvertent inoculation,
ontact vaccinia transfer, or keratitis were observed.
. DiscussionIn our previous studies, diluted ﬁrst-generation vaccine stocks
Lancy-Vaxina vaccine) were effective in both vaccinia-naïve and
reviously vaccinated subjects [14], and the newly developed cell
Fig. 1. Flow diagram of theModerate symptoms were bothersome but did not preclude the performance of
routine activities.
c Severe symptoms precluded the performance of routine activities.
culture-derived second-generation vaccine (CJ-50300 vaccine) was
effective and safe in healthy vaccinia-naïve adults [11]. However,
responses to the CJ-50300 vaccine in vaccinia-experienced adults
have not previously been examined. In this study, we  demonstrated
that the CJ-50300 vaccine was effective in evoking cutaneous take
reactions and PRN responses in healthy adults previously vacci-
nated against smallpox.
Of  the 139 eligible vaccinees, 132 (95.0%) generated a take reac-
tion, which is signiﬁcantly higher than the minimal effective rate
of 86% (P = 0.0012), calculated on the basis of previous reports [13].
Our result is consistent with previous studies by us [14] and others
[15–17] using a ﬁrst-generation vaccine in previously vaccinated
subjects.
Several previous studies have suggested that humoral immunity
against smallpox, based on neutralizing activity against vaccinia
virus, is long-lived and can persist for more than 20 years after
vaccination [14,18–20]. Consistent with these ﬁndings, 91 (63.2%)
of the participants had measurable antibody titers before receiv-
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han 30 years previously. The prevaccination antibody titer was
igniﬁcantly higher (P < 0.001) than in the historical data from our
revious study in vaccinia-naïve persons [11] (Supplement ﬁgure).
t is of note that the PRNT50 values are presumptive and no abso-
ute correlate of immunity to smallpox has been established [21]. It
s also noteworthy that the vesicles produced were smaller in the
accinia-experienced group than the vaccinia-naïve group (Supple-
ent Table 1).
Other  studies have also reported fewer adverse events in
accinia-experienced subjects than vaccinia-naïve subjects, pos-
ibly due to immunologic memory [6,13–17]. In agreement with
hose observations, although 95.9% (139/145) of our participants
xperienced at least one systemic or local adverse event, none
xperienced any severe reaction (Table 2). The incidence of mod-
rate adverse events was also lower than in our historic data from
accinia-naïve subjects [11] (Supplement Table 2).
Our  study has some limitations. First, this was a single arm study
imited to vaccinia-experienced adults. Therefore, although we
sed the same protocol as in our previous study in vaccinia-naïve
dults, the efﬁcacy and safety of CJ-50300 in vaccinia-experienced
dults could not be directly compared to that of vaccinia-naïve sub-
ects. Second, CJ-50300 was not directly compared to ACAM2000,
or to ﬁrst-generation smallpox vaccines because they were not
vailable in Korea. Third, as this study included only adults aged
60 years, the vaccine was not assessed in elderly subjects or chil-
ren. This precludes the generalizability of our ﬁndings to all age
roups, and also the ability to assess the frequency of uncommon
dverse events.
In  conclusion, CJ-50300 evoked cutaneous take-reactions and
RN responses in previously vaccinated healthy adults. It was
ot associated with any serious adverse reactions and was well-
olerated overall.
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